CDSCO's Phase III GCT circular: the small print sponsors misread, and what it does to an India-first approval model.
CDSCO's clarification of 10 August 2026 removes an assumption MNC and India-based biotech sponsors had been running on: completing Phase III global clinical trials with Indian subjects does not, by itself, deliver an Indian marketing approval. Applications for drugs not yet approved anywhere in the world are now routed to the IND Division at CDSCO headquarters in New Delhi and processed as full investigational-new-drug reviews under the New Drugs and Clinical Trials Rules, 2019. For biotech investors valuing India-first approvals, this resets timeline assumptions and moves leverage back to CDSCO reviewers.
What a board member needs before the next meeting on this.
- The circular is dated and named. CDSCO issued its clarification on 10 August 2026, filed as F. No. ND-11011(13)/2/2026-eoffice. The subject line is precise: applications to import and market new drugs not approved anywhere in the world where Phase III Global Clinical Trials are ongoing or completed with participation of Indian subjects, under the New Drugs and Clinical Trials Rules, 2019.
- The shortcut sponsors read into the rule is not there. Completion of a Phase III global trial with Indian subjects does not, on its own, deliver a marketing permission in India. Every such application is now examined and processed by the IND Division at CDSCO headquarters in New Delhi. The New Drugs Division confirmed this after an internal technical committee reviewed the growing volume of these filings.
- The scrutiny is comprehensive, not procedural. The IND Division applies the full NDCT Rules 2019 evaluation to both non-clinical and clinical data. For drugs still under review by foreign regulators, that is the same standard applied to any new drug seeking Indian market entry — not a lighter touch because the sponsor generated Indian trial data.
- The timing assumption is what resets. Sponsors modelling an India-first launch based on 'complete Phase III GCT, receive Indian marketing permission' were pricing a schedule that no longer exists. The commercial signal is not that India rejects the pathway; it is that the pathway now sits at the full IND-review clock, not at a fast-track shortcut.
On 10 August 2026 the Central Drugs Standard Control Organisation issued a circular that reads as a paperwork tidy-up and functions as a repricing signal. Filed as F. No. ND-11011(13)/2/2026-eoffice and listed on the CDSCO circulars index with the subject line "Clarification on the submission of applications for grant of Permission to Import and Market New Drugs not approved anywhere in the world, wherein phase III Global Clinical Trials (GCT) are ongoing or completed with participation of Indian subjects under the New Drugs and Clinical Trials Rules, 2019" (CDSCO circular, 10 August 2026, listed on the CDSCO Circulars index). For MNC pharmaceutical sponsors, India-based biotech, and the biotech funds valuing India-first approvals, this closes a route sponsors had been running as if it were open.
THE ROUTE SPONSORS MISREAD
Pharma companies filing for permission to import and market new drugs that are not yet approved anywhere in the world had been treating the participation of Indian subjects in Phase III global clinical trials as a form of qualifying evidence in itself — that completing the trial in India would, in effect, unlock a marketing permission ahead of any foreign regulator's decision. CDSCO's circular says the opposite. The clarification, addressed to sponsors reading the growing volume of such filings as a rising pathway, restates the rule: these applications require the full evaluation of non-clinical and clinical data under the New Drugs and Clinical Trials Rules, 2019, and will be handled by the Investigational New Drug (IND) Division at CDSCO headquarters in New Delhi (CDSCO circular, 10 August 2026). The circular's own wording is that sponsors cannot use Indian-subject participation in a global trial as a shortcut to Indian market approval — the drug goes through the full regulatory process regardless.
WHAT THE CIRCULAR ACTUALLY SAYS
CDSCO's New Drugs Division examined the matter through an internal technical committee. The committee's conclusion, adopted by the regulator, is that Investigational New Drug applications which are under review by foreign regulatory authorities require comprehensive evaluation of non-clinical and clinical data in accordance with the NDCT Rules, 2019 (CDSCO circular, 10 August 2026). CDSCO has therefore directed that all such applications be submitted to and processed by the IND Division at CDSCO Headquarters, New Delhi. The circular is a procedural direction, but the substance is that the reviewing division for these applications has been fixed, the applicable rulebook has been named, and the depth of review — comprehensive, spanning non-clinical and clinical data — has been reaffirmed.
THE NDCT RULES 2019 BAR APPLIES END-TO-END
The New Drugs and Clinical Trials Rules, 2019, are the framework under which any new or investigational drug is evaluated and approved for import or marketing in India. Where a drug has not been approved anywhere in the world, its Indian file is functionally an IND file, and the IND Division is equipped to conduct that assessment. The rule that sponsors had leaned on — that a Phase III global trial completed with Indian subjects offers a data package sufficient to bypass this evaluation — is not written into NDCT 2019. The circular closes the loophole created by inconsistent internal handling within CDSCO's New Drugs Division rather than by the rule itself. Consequently, the review clock a sponsor should have been booking has always been the full IND-Division clock; the market has now been told so on the record.
WHERE THIS RESETS THE MODEL
For an MNC filing an India-first strategy to accelerate revenue on a global asset, the CDSCO clock is now longer than the informal shortcut had implied. If the parallel foreign-regulator clock is on a slower cycle, the India-first thesis survives — but the discount to the foreign timeline is narrower. For an India-based biotech with a portfolio built on Indian trial participation as a route to Indian approval ahead of any other market, the model that assumed the New Drugs Division would process the file on the strength of Indian data alone no longer reflects the reviewing division or the rulebook. For biotech investors valuing the India-first pathway as a premium in a fund model, the leverage has moved back to CDSCO's IND Division reviewers, and the timing sensitivity in an underwriting case that assumes 12-month Indian marketing permission on Phase III GCT completion needs a rebase to a full IND review.
THE COMMERCIAL SIGNAL, NOT THE PROTECTIONIST ONE
CDSCO has not closed the pathway; it has clarified the division that owns it and the scrutiny it carries. The signal to read is not that India is now hostile to first-in-the-world filings — it is that the regulator has chosen a route that treats these drugs like any other novel therapeutic and prices the review accordingly. A sponsor that came to the market on the assumption of a lighter touch got a firm reminder that CDSCO is not the vector for a shortcut. A sponsor that came to the market having already sequenced its Indian filing behind a full IND package has, in effect, been de-risked — the circular protects its timing assumption from competitors filing thinner packages. The commercial signal cuts both ways, and the operating question is which side of it the sponsor sits on right now.
Four questions before rebasing an India-first approval model
- Which pipeline assets are we carrying at a valuation that assumes a Phase III GCT with Indian subjects delivers an Indian marketing permission without a full IND-Division review, and how far off are those timing assumptions now?
- For assets already in Phase III with Indian centres enrolled, does our submission strategy already treat the IND Division as the reviewing authority — or is our CDSCO liaison working the New Drugs Division as if the shortcut still exists?
- How does the IND Division's non-clinical + clinical evaluation timing compare with the parallel foreign-regulator clock we are running, and which market now realistically approves first?
- Where in the deal thesis do we assume an Indian-first launch valuation premium that survives the resetting of the CDSCO clock, and which sensitivity holds?
The Monday work is finite. Pull every pipeline asset flagged for an India-first filing on a Phase III GCT basis and rebase the timing assumption against a full IND-Division review under NDCT 2019. Reroute the CDSCO liaison for those files to the IND Division at New Delhi headquarters, not the New Drugs Division. Rebuild the fund-model sensitivity on the India-first premium so that the base case is a full IND clock, not the shortcut. That filing and pathway work is where our market access and regulatory practice begins.
This brief covers one instrument. The UAE healthcare regulatory tracker carries the full set — DoH, DHA, EDE and the other emirates — with what each one changes and when it takes effect.
Subscribe
The UAE healthcare regulatory briefing
What changed, what it reprices, and the instrument to read. Every second Tuesday. No pitches.
One email a fortnight. Unsubscribe from any of them.